<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pmed.1002882.t002" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pmed.1002882.t002</object-id>
 <label>Table 2</label>
 <caption>
  <title>Ongoing and planned clinical trials in pregnant and lactating women (as of December 2018).</title>
 </caption>
 <alternatives>
  <graphic id="pmed.1002882.t002g" xlink:href="pmed.1002882.t002" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Study/Trial Number</th>
     <th align="left" rowspan="1" colspan="1">Funding/Sponsor</th>
     <th align="left" rowspan="1" colspan="1">Phase</th>
     <th align="left" rowspan="1" colspan="1">TB Type</th>
     <th align="left" rowspan="1" colspan="1">Purpose</th>
     <th align="left" rowspan="1" colspan="1">Design</th>
     <th align="left" rowspan="1" colspan="1">Regimen</th>
     <th align="left" rowspan="1" colspan="1">Study Population</th>
     <th align="left" rowspan="1" colspan="1">Location</th>
     <th align="left" rowspan="1" colspan="1">Status</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" colspan="10" rowspan="1">LTBI</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT P2001/NCT02651259</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">I/II</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">PK, tolerability, and safety of 3HP for LTBI</td>
     <td align="left" rowspan="1" colspan="1">Open-label, non-randomized trial</td>
     <td align="left" rowspan="1" colspan="1">12 once-weekly doses of P and H (3HP)</td>
     <td align="left" rowspan="1" colspan="1">Pregnant (≥14 weeks GA)/lactating women (18 years+), 
      <bold>HIV+ (any CD4, compatible ARV)/</bold>HIV−, with LTBI or known recent pulmonary TB exposure
     </td>
     <td align="left" rowspan="1" colspan="1">Haiti, Kenya, Malawi, Thailand, Zimbabwe</td>
     <td align="left" rowspan="1" colspan="1">Fully accrued/ results expected early 2020</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT P1078/NCT01494038</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Safety of antepartum versus postpartum-initiated IPT for TB prevention in HIV+ pregnant women in high-TB-burden settings</td>
     <td align="left" rowspan="1" colspan="1">Randomized, double-blind, placebo-controlled trial</td>
     <td align="left" rowspan="1" colspan="1">Immediate H (entry through week 28), then placebo through week 40 postpartum versus placebo (entry through week 12 postpartum), then H through week 40 postpartum</td>
     <td align="left" rowspan="1" colspan="1">Pregnant (≥14 weeks GA)/lactating women (13 years+), 
      <bold>HIV+ (any CD4, any ARV</bold>) without active TB
     </td>
     <td align="left" rowspan="1" colspan="1">Botswana, Haiti, India, South Africa, Tanzania, Thailand, Uganda, Zimbabwe</td>
     <td align="left" rowspan="1" colspan="1">Completed/ primary results presented CROI 2018 [
      <xref rid="pmed.1002882.ref049" ref-type="bibr">49</xref>]
     </td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT CS 5021</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Safety, tolerability, optimal timing, and PK of 1HP versus 3HP in pregnant and postpartum women</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized, 4-arm factorial design trial</td>
     <td align="left" rowspan="1" colspan="1">1HP versus 3HP in HIV-infected pregnant and postpartum women</td>
     <td align="left" rowspan="1" colspan="1">Recently exposed or LTBI+, 
      <bold>HIV+ (any CD4, compatible ARV)</bold> pregnant (≥24 weeks GA) women; subset of HIV− for PK and safety under consideration
     </td>
     <td align="left" rowspan="1" colspan="1">Multisite international</td>
     <td align="left" rowspan="1" colspan="1">Planned</td>
    </tr>
    <tr>
     <td align="left" colspan="10" rowspan="1">DS TB</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Tshepiso</td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK of first-line TB drugs</td>
     <td align="left" rowspan="1" colspan="1">Open-label, nonrandomized trial</td>
     <td align="left" rowspan="1" colspan="1">First-line TB drugs with and without ARVs</td>
     <td align="left" rowspan="1" colspan="1">
      <bold>HIV+ (any CD4, any ARV)</bold>/HIV− pregnant and postpartum/lactating women
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Completed. Some results published [
      <xref rid="pmed.1002882.ref041" ref-type="bibr">41</xref>,
      <xref rid="pmed.1002882.ref044" ref-type="bibr">44</xref>,
      <xref rid="pmed.1002882.ref045" ref-type="bibr">45</xref>]
     </td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">PK of first-line TB drugs in pregnancy</td>
     <td align="left" rowspan="1" colspan="1">NIH NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">PK of first-line TB drugs</td>
     <td align="left" rowspan="1" colspan="1">Open-label, nonrandomized trial</td>
     <td align="left" rowspan="1" colspan="1">First-line TB drugs with and without ARVs</td>
     <td align="left" rowspan="1" colspan="1">
      <bold>HIV+ (any CD4, any ARV</bold>)/HIV− pregnant and postpartum/lactating women
     </td>
     <td align="left" rowspan="1" colspan="1">India</td>
     <td align="left" rowspan="1" colspan="1">Ongoing</td>
    </tr>
    <tr>
     <td align="left" colspan="10" rowspan="1">DR TB</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">VirTUAL/NCT03923231</td>
     <td align="left" rowspan="1" colspan="1">EDCTP</td>
     <td align="left" rowspan="1" colspan="1"/>
     <td align="left" rowspan="1" colspan="1">DS/DR</td>
     <td align="left" rowspan="1" colspan="1">PK/PD modeling to predict doses for pregnant women, lactating women, and children</td>
     <td align="left" rowspan="1" colspan="1">PK studies and modeled data</td>
     <td align="left" rowspan="1" colspan="1">First- and second-line TB drugs with and without ARVs</td>
     <td align="left" rowspan="1" colspan="1">
      <bold>HIV+</bold>/HIV− pregnant (≥20 weeks GA) and lactating women on first-line TB treatment or second-line MDR TB treatment.
      <break/>NCT03923231 assessing atazanavir/ritonavir with rifampin, specifically
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa, Uganda, United Kingdom, and Italy</td>
     <td align="left" rowspan="1" colspan="1">Ongoing</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ACTG 5300B IMPAACT2003B/NCT03568383</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy and safety of De versus IPT for MDR TB prevention in high-risk household contacts (HIV+, non-HIV immunosuppression, LTBI, and children &lt;5 years)</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">De ×26 weeks versus H ×26 weeks</td>
     <td align="left" rowspan="1" colspan="1">Children and adult household contacts of MDR TB case, 
      <bold>HIV+ (any CD4, any ARV</bold>)/HIV−, possible opportunistic substudy of PK among women who become pregnant during study drug intake
     </td>
     <td align="left" rowspan="1" colspan="1">27 sites on 3 continents</td>
     <td align="left" rowspan="1" colspan="1">Accrual expected to start mid-2019. Pregnancy study under consideration</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">BDQ in pregnancy</td>
     <td align="left" rowspan="1" colspan="1">South Africa MRC</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">PK of BDQ in pregnancy</td>
     <td align="left" rowspan="1" colspan="1">Open-label, nonrandomized trial</td>
     <td align="left" rowspan="1" colspan="1">BDQ in optimized regimen</td>
     <td align="left" rowspan="1" colspan="1">
      <bold>HIV+</bold> (
      <bold>any CD4, compatible ARV)</bold>/HIV− pregnant and postpartum women on MDR TB treatment
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Ongoing</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT P1026s/NCT00042289</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS/DR</td>
     <td align="left" rowspan="1" colspan="1">PK of ARVs and first- and second-line TB drugs (including BDQ and De) in pregnant women and their infants and ARVs in postpartum before/after initiation of hormonal contraceptives</td>
     <td align="left" rowspan="1" colspan="1">Open-label, nonrandomized trial</td>
     <td align="left" rowspan="1" colspan="1">ARVs without TB drugs; ARVs with TB drugs; no ARVs with TB drugs; +/− ARVs with second-line TB drugs; ARVs with postpartum hormonal contraceptives</td>
     <td align="left" rowspan="1" colspan="1">
      <bold>HIV+ (any CD4, compatible ARV)</bold>/HIV− pregnant (≥20 weeks GA) and postpartum/lactating women on first-line TB treatment or second-line MDR TB treatment
     </td>
     <td align="left" rowspan="1" colspan="1">US and international sites (TB mostly from South Africa)</td>
     <td align="left" rowspan="1" colspan="1">Accrual expected mid-2019/ results expected 2025</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">IMPAACT 2026</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID, NICHD</td>
     <td align="left" rowspan="1" colspan="1">IV</td>
     <td align="left" rowspan="1" colspan="1">DS/DR</td>
     <td align="left" rowspan="1" colspan="1">PK of first- and second-line TB drugs in pregnant women with and without HIV</td>
     <td align="left" rowspan="1" colspan="1">Open-label, nonrandomized trial</td>
     <td align="left" rowspan="1" colspan="1">ARVs, contraception, and TB-related drugs during and after pregnancy</td>
     <td align="left" rowspan="1" colspan="1">HIV−
      <bold>/HIV+ (any CD4, compatible ARV)</bold>, pregnant (≥20 weeks GA) and postpartum/lactating women on first-line TB treatment or second-line MDR TB treatment
     </td>
     <td align="left" rowspan="1" colspan="1">TBD</td>
     <td align="left" rowspan="1" colspan="1">Concept sheet in development</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t002fn001">
   <p>IMPAACT trial protocols can be found at 
    <ext-link ext-link-type="uri" xlink:href="https://impaactnetwork.org/studies/index.asp" xmlns:xlink="http://www.w3.org/1999/xlink">https://impaactnetwork.org/studies/index.asp</ext-link>; NCT is the 
    <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/</ext-link> identification number; trials including HIV-infected (HIV+) are demarcated using bolded “HIV+” in the Study Population column.
   </p>
  </fn>
  <fn id="t002fn002">
   <p>Abbreviations: 1HP, 1 month of daily H and P; 3HP, 3 months of weekly H and P; ACTG, AIDS Clinical Trials Group; ARV, antiretroviral; BDQ, bedaquiline; CROI, Conference on Retroviruses and Opportunistic Infections; De, delaminid; DS, drug-sensitive; DR, drug-resistant; EDCTP, European &amp; Developing Countries Clinical Trials Partnership; GA, gestational age; H, isoniazid; HIV, human immunodeficiency virus; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trials Network; IPT, isoniazid preventive therapy; LTBI, latent TB infection; MDR, multidrug-resistant; MRC, Medical Research Council; NIH, National Institutes of Health; NIAID, National Institute of Allergy and Infectious Diseases; NICHD, Eunice Kennedy Shriver National Institute of Child Health and Human Development; P, rifapentine; PD, pharmacodynamics; PK, pharmacokinetics; TB, tuberculosis; TBD, to be determined</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
